Chronic Myelomonocytic Leukaemia (CMML)

Seeing Cancer From All Sides: Richard M. Stone Is Giant of Cancer Care in Leukemia

Original Publication Date
Article Source
External Web Content
Driven by his mother’s advice and his father’s memory, Richard M. Stone, MD, rose to become a global leader in leukemia care and research. Growing up, Richard M. Stone, MD, thought he was going to be an attorney like his father, but his direction in life changed when he was 15…

Science Simplified: What is a Natural History Study?

Original Publication Date
Article Source
External Web Content
Want to learn about scientific topics without needing a PhD? Check out the Science Simplified blog from TESS Research Foundation! Dr. Tanya Brown, PhD, works with researchers to make science accessible and empower rare disease community members with scientific knowledge. Dr…

Genetic Testing for Bone Marrow Failure Diseases

Thumbnail for video Watch Now

Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
Presenter(s)
Jadee Neff, M.D., Ph.D., FCAP
In this webinar, Dr. Jadee Neff discusses how genetic testing used in the diagnostic process, how it can help identify possible causes of disease that inform decisions regarding appropriate therapies, identify potential donors for bone marrow transplant, and potential risk for…

Clinical Trials and Children

Until recently, children were rarely included in studies of medical treatments. As a result, much is still unknown about how children respond to drugs, some biologics (such as gene therapy) and medical devices. According to the U.S. Food and Drug Administration (FDA), only 20-30% of approved drugs have actually been labeled for use in children.

mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS

Original Publication Date
Article Source
External Web Content
The mRNA COVID-19 Vaccines Are Safe and Effective for Most Patients with Cancer For most patients with cancer, the mRNA COVID-19 vaccines are safe and effective. This article explains the results of the first study that evaluated the safety and effectiveness of the mRNA vaccines…

ASTEX PHARMACEUTICALS PRESENTS OVERALL SURVIVAL DATA FROM ASCERTAIN PHASE 3 STUDY OF ORAL HYPOMETHYLATING AGENT INQOVI® (DECITABINE AND CEDAZURIDINE) IN MDS AND CMML AT INTERNATIONAL CONGRESS ON MYELODYSPLASTIC SYNDROMES

Original Publication Date
Article Source
External Web Content
Study achieved median overall survival of 31.7 months Updated efficacy data demonstrated an overall response rate of 62%, with 22% of patients achieving a complete response INQOVI is the only oral hypomethylating agent with equivalent exposure to its intravenous (IV) form…

Adrienne Phillips, MD, MPH

Institution
Weill Cornell Medical College
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)

Dr. Jason Mendler

Institution
Wilmot Cancer Center
Physician Status
available for consultation
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
About
Jason Harold Mendler, MD, PhD, Assistant Professor of Oncology, received his bachelor's degree, Summa Cum Laude, from Washington University in St. Louis, Missouri. He then went on to earn his PhD in Genetics and his medical degree at the University of Rochester School of Medicine and Dentistry in Rochester, New York. Prior to joining Wilmot Cancer Center, Dr. Mendler completed his residency at and served as chief resident of the University of Rochester Medical Center, Department of Medicine. Most recently, he completed a clinical fellowship in oncology at Ohio State University Medical Center

Eunice Wang, MD

Institution
Roswell Park Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
About
Dr. Eunice Wang is the Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center. Dr. Wang joined the Roswell Park faculty in 2003 and was appointed to the Leukemia Service of the Department of Medicine. She earned her medical degree from the Keck School of Medicine, University of Southern California and completed residency training in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT in 1999. From 1999 to 2003, she completed a clinical hematology-oncology and research fellowship at Memorial Sloan Kettering Cancer Center in New York, NY. She is

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.